Teleflex Incorporated (TFX)
US — Healthcare Sector
Automate Your Wheel Strategy on TFX
With Tiblio's Option Bot, you can configure your own wheel strategy including TFX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TFX
- Rev/Share 65.7227
- Book/Share 91.6875
- PB 1.3591
- Debt/Equity 0.4702
- CurrentRatio 2.4071
- ROIC 0.0366
- MktCap 5506864808.0
- FreeCF/Share 9.3229
- PFCF 12.7645
- PE 30.0441
- Debt/Assets 0.2705
- DivYield 0.0109
- ROE 0.0449
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | TFX | BofA Securities | Neutral | Underperform | $235 | $140 | March 4, 2025 |
| Downgrade | TFX | Piper Sandler | Overweight | Neutral | $255 | $140 | Feb. 28, 2025 |
| Downgrade | TFX | Raymond James | Outperform | Market Perform | -- | -- | Feb. 28, 2025 |
| Downgrade | TFX | RBC Capital Mkts | Outperform | Sector Perform | $220 | $155 | Feb. 28, 2025 |
| Downgrade | TFX | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | Feb. 27, 2025 |
News
TFX BREAKING NEWS: Teleflex Incorporated 20% Stock Drop Triggers Securities Fraud Investigation; Investors are Urged to Contact BFA Law if they Suffered Losses
TFX
Published: February 27, 2025 by: Business Wire
Sentiment: Neutral
Published: February 27, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)---- $TFX #ClassAction--Teleflex Incorporated investors that lost money are encouraged to contact BFA Law about its ongoing securities fraud investigation.
Read More
Teleflex Hits 52-Week Low On Plan To Split Into Two Companies, Reports Mixed Q4 Earnings
TFX
Published: February 27, 2025 by: Benzinga
Sentiment: Negative
Published: February 27, 2025 by: Benzinga
Sentiment: Negative
On Thursday, Teleflex Incorporated TFX will pursue a plan to separate into two new, independent, publicly traded companies:
Read More
Teleflex (TFX) Surpasses Q4 Earnings Estimates
TFX
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Teleflex (TFX) came out with quarterly earnings of $3.89 per share, beating the Zacks Consensus Estimate of $3.86 per share. This compares to earnings of $3.38 per share a year ago.
Read More
About Teleflex Incorporated (TFX)
- IPO Date 1980-03-17
- Website https://www.teleflex.com
- Industry Medical - Instruments & Supplies
- CEO Liam J. Kelly
- Employees 14100
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.